Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Oklahoma City, Oklahoma 73104


Purpose:

RATIONALE: Studying the genes expressed in samples of blood and cervix tissue from patients with a cervical abnormality may help doctors identify biomarkers related to cancer. PURPOSE: This clinical trial is studying biomarkers in women at high risk for developing cervical cancer.


Study summary:

OBJECTIVES: - Assess biomarkers of risk for progressive cervical neoplasia that can distinguish patients at highest risk for cervical cancers from patients with benign infection. - Develop a comprehensive list of potential risk biomarkers by examining cervical tissues of women with normal, human papilloma virus (HPV) infection, precancer, and cancer. - Measure gene expression profiles to gain an accurate and comprehensive in vivo picture of cervical neoplasia carcinogenesis. - Assess the predictive values of candidate biomarkers for key outcomes related to progression (i.e., HPV persistence, diagnosis of precancer) or nonprogression (i.e., HPV clearance). OUTLINE: Patients complete a questionnaire on health-related issues, undergo blood collection and cervix tissue collection along with biopsy for research purposes, and have photographs of the cervix taken. Cells and secretions from the cervix are also collected and tested for human papilloma virus infection. The procedure lasts approximately 1 hour. Information about patients' health and medical records is stored in a data repository. Patients are followed within 6 weeks after completion of the initial study visit and periodically thereafter for up to 5 years.


Criteria:

DISEASE CHARACTERISTICS: - Abnormal result on most recent pap smear - Must have been considered for any of the following cervical procedures by a physician: - Colposcopy - Cervical biopsy - Treatment of a cervical abnormality - Hysterectomy PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified


NCT ID:

NCT00558389


Primary Contact:

Principal Investigator
Sophia S. Wang
National Cancer Institute (NCI)


Backup Contact:

N/A


Location Contact:

Oklahoma City, Oklahoma 73104
United States

Contact Person
Phone: 301-402-5347

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.